Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

Da Som Jeon; Ho Cheol Kim; Se Hee Kim; Tae-Jung Kim; Hong Kwan Kim; Mi Hyung Moon; Kyongmin Sarah Beck; Yang-Gun Suh; Changhoon Song; Jin Seok Ahn; Jeong Eun Lee; Jeong Uk Lim; Jae Hyun Jeon; Kyu-Won Jung; Chi Young Jung; Jeong Su Cho; Yoo-Duk Choi; Seung-Sik Hwang; Chang-Min Choi; Korean Association for Lung Cancer; Korea Central Cancer Registry

doi:10.4143/crt.2022.264

Articles

Page Path: HOME > Cancer Res Treat > Volume 55(1); 2023 > Article

Original Article Lung and Thoracic cancer Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015: Da Som Jeon¹, Ho Cheol Kim¹, Se Hee Kim², Tae-Jung Kim³, Hong Kwan Kim⁴, Mi Hyung Moon⁵, Kyongmin Sarah Beck⁶, Yang-Gun Suh⁷, Changhoon Song⁸, Jin Seok Ahn⁹, Jeong Eun Lee¹⁰, Jeong Uk Lim¹¹, Jae Hyun Jeon¹², Kyu-Won Jung¹³, Chi Young Jung¹⁴, Jeong Su Cho¹⁵, Yoo-Duk Choi¹⁶, Seung-Sik Hwang¹⁷, Chang-Min Choi^1,18, Korean Association for Lung Cancer, Korea Central Cancer Registry; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2023;55(1):103-111.
DOI: https://doi.org/10.4143/crt.2022.264
Published online: June 20, 2022

¹Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

²Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

³Department of Hospital Pathology, Yeouido St. Mary’s hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁴Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁵Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁶Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁷Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, Korea

⁸Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

⁹Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

¹⁰Division of Pulmonology, Chungnam National University College of Medicine, Daejeon, Korea

¹¹Division of Pulmonary, Allergy and Critical Care Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

¹²Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

¹³Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea

¹⁴Department of Pulmonary, Daegu Catholic University Medical Center, Daegu Catholic University School of Medicine, Daegu, Korea

¹⁵Department of Thoracic and Cardiovascular Surgery, Pusan National University Hospital, Busan, Korea

¹⁶Department of Pathology, Chonnam National University Medical School, Gwangju, Korea

¹⁷Department of Public Health Science, Graduate School of Public Healthy, Seoul National University, Seoul, Korea

¹⁸Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence: Chang-Min Choi, Department of Pulmonary and Critical Care Medicine and Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olymphic-ro 43-gil, Songpa-gu, Seoul 05505, Korea,
Tel: 82-2-3010-5902, Fax: 82-2-3010-5902, E-mail: ccm@amc.seoul.kr

* Da Som Jeon and Ho Cheol Kim contributed equally to this work.

• Received: April 25, 2022 • Accepted: June 16, 2022

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

9,067 Views
440 Download
38 Web of Science
32 Crossref
40 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.
Materials and Methods
The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.
Results
We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).
Conclusion
In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.
Key words: Lung neoplasms, Epidemiology, Korea, Relative survival rate

Introduction

Lung cancer is the most commonly diagnosed cancer and the leading cause of death worldwide. In Korea, although the mortality of patients with lung cancer has decreased in recent years [1], the mortality rate remains high, regardless of sex [2].

With the development of various therapeutic modalities, such as immunotherapy and targeted therapy, the overall lung cancer survival rate, which has been stagnant for decades, has improved [3]. However, although the 5-year survival rates in lung cancer varied depending on the clinical stage, all stages have low 5-year survival rates of only around 22% [4]. Especially in the United States, among patients diagnosed with non–small cell lung cancer (NSCLC) from 2011 to 2017, the 5-year relative survival rate was 26% in all stages and only 8% in cases with distant metastases. Small cell lung cancer (SCLC) had a substantially lower 5-year relative survival rate of approximately 7% for the same time period [5].

Several studies have suggested that race and geography may have a role in lung cancer mortality [6]. According to recent domestic data, the 5-year lung cancer relative survival rate is reported as 63.7% in male and 84.3% in female for localized stage, in addition, 7.0% in male and 13.4% in female for distant stage [2]; however, there have been no large samples of domestic data on how the histopathologic subtype, clinical staging, and prognostic factors affect the 5-year survival rate of lung cancer.

Therefore, the aim of this study was to investigate the clinical characteristics and prognostic factors for the 5-year overall survival in patients with lung cancer using data from the KA-LC-R (Korean Association of Lung Cancer Registry) from 2015.

Materials and Methods

1. Study design and subjects

This study analyzed data from the KALC-R cohort—the second nationwide survey, a multi-center cancer Registry from 64 institutions with more than 400 beds in Korea [7]. In 2015, the KALC registered 2,657 patients who were newly diagnosed with lung cancer. The KALC-R has approximately 80 data fields comprising demographic data. Data on patient age, sex, body mass index (BMI), symptoms, smoking history, performance status (PS), histopathologic type, clinical stage (according to the eighth edition of the TNM International Staging System), initial treatment modality, results of molecular tests (i.e., epidermal growth factor receptor [EGFR] mutation and anaplastic lymphoma kinase [ALK] translocation) were collected using a standardized protocol. Information such as BMI, symptoms, and smoking history was obtained at the initial visit at the time of diagnosis. Patients were followed up until December 2020.

2. Statistical analysis

Relative survival was developed to provide an objective assessment of cancer survival while accounting for disparities in mortality from other causes. Relative survival was defined as the ratio of the observed survival of a cohort of patients with cancer to the expected survival of a comparable group of cancer-free individuals. The relative survival rates were estimated using the Ederer II method, with some minor corrections based on an algorithm devised by Paul Dickman [8]. The 5-year relative survival rate was defined as the ratio of the observed survival of patients with cancer to the expected survival in the general population. The general population data used the source data for the death rate per 100,000 people adjusted for sex and age from 2015 to 2020, published by the Korea Statistical Information Service [9].

Data are expressed as the mean±standard deviation or median (interquartile range [IQR]). The Mann-Whitney U test was used to compare continuous variables, and the chi-square or Fisher’s exact test was used to compare categorical variables. Cox proportional hazards models were used to investigate mortality risk factors. Variables with a p-value < 0.20 on univariate analysis were used in multivariate analysis. Survival was analyzed by the Kaplan-Meier method. All p-values < 0.05 were considered statistically significant. All statistical analyses were performed using SPSS software ver. 27.0 (IBM Corp., Armonk, NY).

Results

1. Baseline characteristics

We enrolled a total of 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with NSCLC and 345 (13.0%) were diagnosed with SCLC.

Patients diagnosed with NSCLC were analyzed by dividing them into survivor and non-survivor group (Table 1). Among the 2,098 patients with NSCLC, 1,446 (68.9%) died and 652 (31.1%) survived during the follow-up period. The median patient age was significantly older (70.0 [IQR, 62.0 to 76.0 years] vs. 65.0 [IQR, 57.0 to 72.0 years], p < 0.001) in the non-survivor group. The proportions of male sex (75.4% vs. 57.2%, p < 0.001) and ever-smoker status (67.5% vs. 54.0%, p < 0.001) were significantly higher in the non-survivor group.

Regarding the histopathology, adenocarcinoma was the leading subtype (62.3%) in patients with NSCLC, and adenocarcinoma was more common (56.0% vs. 76.4%, p < 0.001) in the survivor group. In addition, the proportions of patients with early-stage (stage I or II) NSCLC (17.1% vs. 76.2%, p < 0.001) and good PS (83.8% vs. 98.1%, p < 0.001) were higher in the survivor group.

Among the 345 patients diagnosed with SCLC in 2015, 321 (93.0%) died and only 24 (7.0%) survived during the follow-up period (Table 2). There were no significant differences in male sex (84.7% in non-survivor vs. 83.3% in survivor group, p=0.854), ever-smoker status (83.5% vs. 87.5%, p=0.381), BMI (25.9 vs. 22.5, p=0.166), subjective symptoms, and good PS (83.6% vs. 87.5%, p=0.681) between the two groups. The median patient age was significantly older (72.0 [IQR, 63.0 to 77.0 years] vs. 67.5 [IQR, 60.0 to 71.0 years], p=0.023), and the proportion of extended disease (63.9% vs. 33.3%, p=0.004) was significantly higher in the non-survivor group (Table 2).

2. Initial treatment methods

The initial treatment modalities of NSCLC patients was presented in S1 Table. In the survivor group, the proportion of surgery was higher than that of the non-survivor group (8.0% in non-survivor group vs. 67.6% in survivor group, p < 0.001). In the non-survivor group, the proportion of radiotherapy (10.0% vs. 4.4%, p < 0.001), concurrent chemoradiation therapy (14.1% vs. 5.5%, p < 0.001), chemotherapy (19.2% vs. 8.9%, p < 0.001), and best supportive care (31.1% vs. 6.3%, p < 0.001) was higher than that of the survivor group. Treatment for each clinical stage in the NSCLC was presented in S2 Table.

The initial treatment modalities of SCLC patients was presented in S3 Table. In SCLC, there was no statistical difference in each treatment methods between survivor and non-survivor groups.

3. Prognostic factor

In total, 2,098 patients with NSCLC were followed up for a median of 20.5 months (IQR, 6.0 to 61.0 months). Univariate Cox analysis showed that old age (hazard ratio [HR], 1.032; 95% confidence interval [CI], 1.027 to 1.038; p < 0.001), male sex (HR, 1.714; 95% CI, 1.520 to 1.933; p < 0.001), ever-smoker status (HR, 1.490; 95% CI, 1.332 to 1.667; p < 0.001), poor PS (HR, 3.172; 95% CI, 2.681 to 3.753; p < 0.001), higher clinical stage (HR, 8,574; 95% CI, 6.836 to 10.754; p < 0.001; stage IV compared to stage I), squamous cell carcinoma (HR, 1.648; 95% CI, 1.476 to 1.841; p < 0.001) histopathology compared to adenocarcinoma, and non-surgical treatment (HR 6.889; 95% CI, 5.708 to 8.314; p < 0.001) or best supportive care (HR, 10.232; 95% CI, 8.399 to 12.466; p < 0.001) compared to surgery were significant predictors of mortality. On multivariate Cox analysis in these variables, except for male sex and ever-smoker status, remained significant prognostic factors (Table 3).

The 345 patients with SCLC were followed up for a median 7 months (IQR, 3 to 16 months). Univariate and multivariate Cox analyses showed that older age, ever-smoker status, poor PS, and extensive stage were significant predictors of mortality (Table 4). There was no significant difference in survival rate according to the treatment methods.

4. Survival analysis

The 5-year actual survival rates of patients with NSCLC was 0.78 for stage I, 0.55 for stage II, 0.15 for stage III, and 0.10 for stage IV. In addition, in patients with SCLC was 0.15 in those with limited disease, and 0.04 in patients with extensive disease.

In the Kaplan-Meier survival curve according to clinical stage of NSCLC, as determined by the eighth edition of TNM, advanced stage demonstrated worse survival probability (Fig. 1). The 5-year relative survival rates of patients with NSCLC was 0.82 for stage I, 0.59 for stage II, 0.16 for stage III, and 0.10 for stage IV (Table 5).

In the Kaplan-Meier survival curve according to the SCLC clinical stage, the extensive stage demonstrated worse survival probability (Fig. 2). The 5-year relative survival rates of patients with SCLC was 0.16 in those with limited disease, and 0.04 in patients with extensive disease (Table 6).

5. Subgroup analysis in patients with stage IV adenocarcinoma

Among the 348 patients with stage IV adenocarcinoma at diagnosis, 310 patients (89.1%) died and 38 patients (10.9%) survived. There were no significant differences in sex, age, ever-smoker status, BMI, subjective symptoms, and PS bet-ween the two groups. EGFR mutation status was analyzed in 304 patients (87.4%), and 118 patients (38.8%) had mutations. ALK translocation was analyzed in 233 patients (67.0%), and 19 patients (8.2%) showed ALK translocation. The ALK translocation frequency (5.7% vs. 29.2%, p < 0.001) was significantly higher in the survival group (S4 Table). The 348 patients with stage IV adenocarcinoma were followed up for a median of 14 months (IQR, 6 to 37 months). On univariate Cox analysis, older age (HR, 1.023; 95% CI, 1.013 to 1.022; p < 0.001), male sex (HR, 1.439; 95% CI, 1.143 to 1.812; p=0.002), ever-smoker status (HR, 1.405; 95% CI, 1.122 to 1.760; p=0.003), poor PS (HR, 2.327; 95% CI, 1.630 to 3.323; p < 0.001), EGFR mutation (HR, 0.651; 95% CI, 0.508 to 0.834; p < 0.001), and ALK translocation (HR, 0.442; 95% CI, 0.246 to 0.792; p=0.006) were associated with mortality. On multivariate Cox analysis, ever-smoker status (HR, 1.756; 95% CI, 1.080 to 2.855; p=0.023), poor PS (HR, 1.675; 95% CI, 1.082 to 2.594; p=0.021), and treatment with EGFR inhibitor (HR, 0.468; 95% CI, 0.262 to 0.835; p=0.010) remained significant independent predictors of mortality (S5 Table).

In the Kaplan-Meier survival curve according to the EGFR mutation and ALK translocation in stage IV adenocarcinoma, better survival probability was observed when EGFR or ALK was expressed (S6 Fig.). The 5-year relative survival rate was 0.11 in the EGFR-negative group, and 0.19 in the EGFR mutation group. In addition, the 5-year relative survival rates were 0.11 in the negative ALK group, and 0.38 in the ALK translocation group.

Discussion

In this nationwide survey, 2,657 patients with newly diagnosed with lung cancer in 2015 were followed up for a median of 16 months (IQR, 4 to 60 months). Among the included patients, 69.0% of patients with NSCLC and 93% of patients with SCLC died. The 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, while those of SCLC were 16% for patients with limited disease, and 4% for patients with extensive disease. To the best of our knowledge, this is the first nationwide-based study in Korea to focus on the 5-year survival of patients with lung cancer.

The KALC-R was created in 2013 to produce unbiased and reliable demographic data, following which, the data were collected annually. According to a previous study that analyzed the epidemiology and characteristics of patients with lung cancer in Korea using the KALC-R data in 2014 [10], adenocarcinoma (48.4%) was the most common histopathology type and was more common in women (74.8% vs. 38.0%, p < 0.001). In addition, more than 1/3 of patients with lung cancer had no smoking history, and the proportion of never-smokers was higher in women (87.5% vs. 16.0%, p < 0.001). In all histopathological types, old age and advanced clinical stage were significant risk factors for mortality. In our study, old age, poor PS, advanced clinical stage, squamous cell carcinoma compared to adenocarcinoma, and non-surgical treatment or best supportive care compared to surgery were independent prognostic factors in NSCLC, which is comparable to the findings of previous studies [11]. It is well known that old age is an important prognostic factor of NSCLC, and females have a better prognosis at a similar age and clinical stage than men [12]. In a large study that analyzed 2,500 patients, age < 70 years, female sex, and good PS were important factors that were predictive of favorable survival rate [13]. Additionally, in a previous systematic review, stage III and IV, and hypercalcemia were predictive factors in NSCLC [11]. In a Japanese lung cancer Registry survey over a 15-year period [14], PS, clinical stage, sex, age, and smoking status were all independent prognostic variables for survival in NSCLC. Recent data have shown that nutritional status and BMI are related to the prognosis of NSCLC, although further research is necessary.

In SCLC, old age, poor PS, and extensive disease were independent prognostic factors in our study. Previous studies reported that old age, male sex, and lower education level were associated with increased mortality of SCLC [15]. In another Korean single-center study [16], the extent of disease and PS were independent prognostic factors for long-term survival of SCLC. Compared to anti-cancer treatment, best supportive care showed no significant difference in prognosis, which is thought to be due to the poor prognosis of SCLC, resulting in a small number of survivors (< 25 patients) (S5 Table). Conventional chemotherapy with immunotherapy such as atezolizumab has recently been used for the treatment of SCLC in clinical practice, and efforts to identify biomarkers are ongoing [17]. Further research is needed on the factors responsible for improving the survival rate of SCLC.

In our study, the 5-year relative survival rate of stage III NSCLC was 16%, which was lower than in previous studies [18]. Recently, durvalumab maintenance treatment followed by chemotherapy was demonstrated favorable outcome in stage III NSCLC patients, with the 5-year survival rate 42.9% and progression-free survival was 33.1% in PACIFIC trial [19]. In our current study, patients were enrolled in 2015 year, before durvalumab was established as a treatment, this might be the reason for the survival difference. Further large-scale studies with stage III NSCLC patients who received durvalumab will be needed in near future.

According to clinical stage, differences in survival rate were identified in both NSCLC and SCLC in the present study. In particular, the 8th edition of the TNM classification was revised in 2017. By subdividing T staging than the 7th edition was found to be a superior predictor of prognosis in early stage lung cancer [20]. We used the 8th edition of the TNM classification for analysis in the present study. In particular, the 5-year relative survival rate was useful for identifying temporal trends in population-based cancer research [21], and may be beneficial for presenting survival rates by stage. In the past 40 years, the 5-year relative survival rate of lung cancer had gradually increased from 10.7% in 1973 to 19.8% in 2010 [22]. Between 2011 and 2017, according to the SEER (Surveillance, Epidemiology, and End Results) cancer statistics data [5], the 5-year relative survival rate was 26% in NSCLC and 7% in SCLC. In addition, the relative survival rate of lung cancer was gradually increased over time in Korea [23]. According to the Korea National Cancer Innovation Database, the 5-year relative survival rate was 32.4% from 2014 to 2018 [2]. It will be possible to evaluate the time-trend of lung cancer survival rate by age, sex, and staging in Korea by using the KALC-R data every year, which might serve as a reference value for the epidemiology of lung cancer in Korea.

In the present study, poor PS and EGFR mutation status were independent prognostic factors of stage IV adenocarcinoma. According to the SEER database, male sex, ≥ 65 years, and poor familial support were poor prognostic factors for the overall survival of metastatic lung adenocarcinoma [24]. As previously shown, EGFR mutation was a strong predictive factor for metastatic lung adenocarcinoma. A previous study reported the 5-year survival rate of advanced NSCLC as being < 5% [25], but 14.6% among EGFR mutated metastatic lung adenocarcinoma [26]. In our analysis, the median survival was 58 months in the EGFR mutant group, which was comparable to that of previous studies of over 24 months [27].

There were several limitations in our study. First, this study had a retrospective study design in Korea. However, we believe this data was representative and reduced selection bias because the subjects were recruited from multi-centers and comprised approximately 10% of all lung cancer patients nationwide. Second, the progression-free survival rates could not be analyzed. Third, subgroup analysis could not be performed due to the lack of detailed information on the type of treatment method according to each stage, additional treatment after initial treatment, and treatment after recurrence or metastasis. Indeed, there were few preliminary data, such as initial treatment approaches, and the comprehensive sub-analysis had certain limitations. Fourth, although the large-scale nationwide-based data, the socioeconomic status, and education level were not included in our data, so it was not possible to analyze the effects of these factors on the prognosis of lung cancer. Despite these limitations, to the best of our knowledge, this is the first nationwide study in Korea to focus on the 5-year relative survival of lung cancer.

In this Korean nationwide survey, the 5-year relative survival rate of NSCLC was between 10% and 82%, while that of SCLC was from 4% to 16% according to clinical stage. Our study is valuable as a baseline reference value because it was analyzed based on large-scale domestic data and might be served for basis and trend analysis from future research.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2022-264-S1-Table.pdf

crt-2022-264-S2-Table.pdf

crt-2022-264-S3-Table.pdf

crt-2022-264-S4-Table.pdf

crt-2022-264-S5-Table.pdf

crt-2022-264-S6-Fig..pdf

NOTES

Ethical Statement

The KALC was approved by the Institutional Review Board (IRB) of the National Cancer Center (approval number: NCC2018-0193). The requirement for informed consent was waived by the IRB due to the retrospective nature of the study. All methods were conducted in accordance with the relevant guidelines.

Author Contributions

Conceived and designed the analysis: Jeon DS, Kim HC, Choi CM.

Collected the data: Jeon DS, Kim HC, Kim TJ, Kim HK, Moon MH, Beck KS, Suh YG, Song C, Ahn JS, Lee JE, Lim JU, Jeon JH, Jung KW, Jung CY, Cho JS, Choi YD, Hwang SS, Choi CM.

Contributed data or analysis tools: Jeon DS, Kim HC, Kim SH, Kim TJ, Kim HK, Moon MH, Beck KS, Suh YG, Song C, Ahn JS, Lee JE, Lim JU, Jeon JH, Jung KW, Jung CY, Cho JS, Choi YD, Hwang SS, Choi CM.

Performed the analysis: Jeon DS, Kim HC, Kim SH, Choi CM.

Wrote the paper: Jeon DS, Kim HC, Choi CM.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Acknowledgements

The data used in this study were provided by the Korean Association for Lung Cancer (KALC) and the Ministry of Health and Welfare, Korea Central Cancer Registry (KCCR).

Fig. 1

Overall survival in patients with non–small cell lung cancer (NSCLC), according to clinical stage.

Fig. 2

Overall survival in patients with small cell lung cancer (SCLC), according to clinical stage. ED, extensive disease; LD, limited disease.

Table 1

Baseline characteristics of patients with NSCLC in 2015

	Total	Non-survivor	Survivor	p-value
No. of patients	2,098	1,446 (68.9)	652 (31.1)
Male sex	1,464 (69.8)	1,091 (75.4)	373 (57.2)	< 0.001
Age (yr)	69.0 (60.0–75.0)	70.0 (62.0–76.0)	65.0 (57.0–72.0)	< 0.001
Ever-smoker	1,328 (63.3)	976 (67.5)	352 (54.0)	< 0.001
BMI (kg/m ² )	23.0 (22.2–24.1)	22.9 (21.6–24.2)	23.4 (23.1–23.8)	0.402
Symptoms	2,062	1,419	643
Asymptomatic	322 (15.6)	127 (8.9)	195 (30.3)	< 0.001
Cough	697 (33.8)	548 (38.6)	149 (23.2)	< 0.001
Sputum	406 (19.7)	310 (21.8)	96 (15.0)	< 0.001
Dyspnea	374 (18.1)	320 (22.6)	54 (8.4)	< 0.001
Hoarseness	47 (2.3)	42 (3.0)	5 (0.8)	0.002
Hemoptysis	128 (6.2)	100 (7.0)	28 (4.4)	0.020
Weight loss	116 (5.6)	94 (6.6)	22 (3.4)	0.004
Pain	381 (18.5)	320 (22.6)	61 (9.5)	< 0.001
Histopathology	2,098	1,446	652
Adenocarcinoma	1,308 (62.3)	810 (56.0)	498 (76.4)	< 0.001
Squamous cell carcinoma	662 (31.6)	522 (36.1)	140 (21.5)	< 0.001
Others	247 (11.8)	208 (14.4)	39 (6.0)	< 0.001
Performance status	1,550	1,029	521	< 0.001
0–1	1,371 (88.5)	862 (83.8)	511 (98.1)
2–4	177 (11.4)	167 (16.2)	10 (1.9)
Clinical stage of NSCLC	1,818	1,243	575	< 0.001
I	390 (21.5)	91 (7.3)	299 (52.0)
II	261 (14.4)	122 (9.8)	139 (24.2)
III	653 (35.9)	559 (45.0)	94 (16.3)
IV	514 (28.3)	471 (37.9)	43 (7.5)

Values are presented as the number (%) or median (interquartile range). BMI, body mass index; NSCLC, non–small cell lung cancer.

Table 2

Baseline characteristics of patients with SCLC in 2015

	Total	Non-survivor	Survivor	p-value
No. of patients	345	321	24
Male sex	292 (84.6)	272 (84.7)	20 (83.3)	0.854
Age (yr)	71.0 (63.0–76.0)	72.0 (63.0–77.0)	67.5 (60.0–71.0)	0.023
Ever-smoker	289 (83.8)	268 (83.5)	21 (87.5)	0.381
BMI (kg/m ² )	25.6 (22.4–30.0)	25.9 (22.2–30.9)	22.5 (20.0–24.3)	0.166
Symptoms	342	318	24
Asymptomatic	20 (5.8)	18 (5.7)	2 (8.3)	0.581
Cough	157 (45.9)	146 (45.9)	11 (45.8)	0.973
Sputum	99 (28.9)	95 (29.9)	4 (16.7)	0.177
Dyspnea	108 (31.6)	103 (32.4)	5 (20.8)	0.251
Hoarseness	11 (3.2)	10 (3.1)	1 (4.2)	0.777
Hemoptysis	19 (5.6)	17 (5.3)	2 (8.3)	0.529
Weight loss	31 (9.1)	31 (9.7)	0	0.111
Pain	62 (18.1)	61 (19.2)	1 (4.2)	0.068
Performance status	272	256	16	0.681
0–1	228 (83.8)	214 (83.6)	14 (87.5)
2–4	44 (16.2)	42 (16.4)	2 (12.5)
Clinical stage of SCLC	345	321	24	0.004
LD	122 (35.4)	106 (33.0)	16 (66.7)
ED	213 (61.7)	205 (63.9)	8 (33.3)
Unknown	10 (2.9)	10 (3.1)	0

Values are presented as the number (%) or median (interquartile range). BMI, body mass index; ED, extensive disease; LD, limited disease; SCLC, small cell lung cancer.

Table 3

Risk factors for mortality in patients with NSCLC assessed by Cox proportional hazards model

	Univariate analysis			Multivariate analysis

	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age	1.032	1.027–1.038	< 0.001	1.019	1.012–1.025	< 0.001

Male sex	1.714	1.520–1.933	< 0.001	1.222	0.985–1.516	0.069

Ever-smoker	1.490	1.332–1.667	< 0.001	1.112	0.899–1.375	0.327

BMI	0.998	0.995–1.002	0.444

Performance status

0–1 (ref)	1.000			1.000

2–4	3.172	2.681–3.753	< 0.001	1.995	1.655–2.405	< 0.001

Clinical stage

I (ref)	1.000			1.000

II	2.434	1.855–3.194	< 0.001	1.530	1.084–2.159	0.016

III	7.801	6.241–9.750	< 0.001	3.263	2.407–4.423	< 0.001

IV	8.574	6.836–10.754	< 0.001	3.829	2.814–5.211	< 0.001

Histology

Adenocarcinoma (ref)	1.000			1.000

Squamous cell carcinoma	1.648	1.476–1.841	< 0.001	1.203	1.033–1.402	0.018

Treatment

Surgery (ref)	1.000			1.000

Non-surgical treatment	6.889	5.708–8.314	< 0.001	3.814	2.968–4.902	< 0.001

Best supportive care	10.232	8.399–12.466	< 0.001	5.189	3.945–6.826	< 0.001

BMI, body mass index; CI, confidence interval; NSCLC, non smallcell lung cancer.

Table 4

Risk factors for mortality in patients with SCLC assessed by Cox proportional hazards model

	Univariate analysis			Multivariate analysis

	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age	1.042	1.028–1.056	< 0.001	1.041	1.026–1.057	< 0.001

Male sex	1.079	0.796–1.463	0.622

Ever-smoker	0.685	0.504–0.929	0.015	0.736	0.509–1.062	0.101

BMI	1.000	0.997–1.004	0.787

Performance status

0–1 (ref)	1.000			1.000

2–4	1.943	1.391–2.714	< 0.001	1.838	1.305–2.587	< 0.001

Clinical stage

LD (ref)	1.000			1.000

ED	1.961	1.542–2.493	< 0.001	2.144	1.636–2.810	< 0.001

Treatment

Anti-cancer treatment (ref)	1.000

Best supportive care	1.160	0.924–1.455	0.200

BMI, body mass index; CI, confidence interval; ED, extensive disease; LD, limited disease; SCLC, small cell lung cancer.

Table 5

Five-year relative survival rates of patients with NSCLC according to stage at lung cancer diagnosis

Stage	Time (yr)	No. at risk	No. of deaths	Observed survival rate^a)	Expected survival rate^b)	Relative survival (95% CI)
1	0.0–1.0	390	19	0.95	0.99	0.96 (0.93–0.98)
	1.0–2.0	371	22	0.89	0.98	0.91 (0.88–0.94)
	2.0–3.0	349	22	0.84	0.97	0.87 (0.82–0.90)
	3.0–4.0	327	16	0.80	0.96	0.83 (0.79–0.87)
	4.0–5.0	311	9	0.78	0.94	0.82 (0.77–0.86)
2	0.0–1.0	261	54	0.79	0.98	0.80 (0.75–0.85)
	1.0–2.0	207	26	0.69	0.97	0.72 (0.65–0.77)
	2.0–3.0	181	15	0.64	0.95	0.67 (0.60–0.73)
	3.0–4.0	166	16	0.57	0.94	0.61 (0.55–0.67)
	4.0–5.0	150	7	0.55	0.92	0.59 (0.53–0.66)
3	0.0–1.0	653	349	0.47	0.98	0.47 (0.43–0.51)
	1.0–2.0	304	105	0.30	0.97	0.31 (0.28–0.35)
	2.0–3.0	199	52	0.23	0.96	0.24 (0.20–0.27)
	3.0–4.0	147	27	0.18	0.94	0.20 (0.16–0.23)
	4.0–5.0	120	21	0.15	0.92	0.16 (0.14–0.19)
4	0.0–1.0	514	262	0.49	0.98	0.50 (0.45–0.54)
	1.0–2.0	252	112	0.27	0.97	0.28 (0.24–0.32)
	2.0–3.0	140	42	0.19	0.95	0.20 (0.17–0.24)
	3.0–4.0	98	30	0.13	0.94	0.14 (0.11–0.17)
	4.0–5.0	68	19	0.10	0.92	0.10 (0.08–0.13)

CI, confidence interval; NSCLC, non small cell lung cancer.

^a) Observed survival rate: probability of survival all causes of death in Korean Association of Lung Cancer Registry patients,

^b) Expected survival rate: probability of expected survivors in a comparable cohort of cancer-free general population.

Table 6

Five-year relative survival rates of patients with SCLC according to stage at lung cancer diagnosis

Stage	Time (yr)	No. at risk	No. of deaths	Observed survival rate^a)	Expected survival rate^b)	Relative survival (95% CI)
LD	0.0–1.0	122	56	0.54	0.98	0.55 (0.49–0.64)
	1.0–2.0	66	27	0.32	0.97	0.33 (0.25–0.42)
	2.0–3.0	39	14	0.20	0.96	0.21 (0.14–0.29)
	3.0–4.0	25	5	0.16	0.95	0.17 (0.11–0.25)
	4.0–5.0	20	2	0.15	0.94	0.16 (0.10–0.23)
ED	0.0–1.0	213	156	0.27	0.98	0.27 (0.21–0.33)
	1.0–2.0	57	41	0.08	0.97	0.08 (0.05–0.12)
	2.0–3.0	16	6	0.05	0.96	0.05 (0.03–0.08)
	3.0–4.0	10	1	0.04	0.95	0.04 (0.02–0.08)
	4.0–5.0	9	1	0.04	0.95	0.04 (0.02–0.07)

CI, confidence interval; ED, extensive disease; LD, limited disease; SCLC, small cell lung cancer.

^a) Observed survival rate: probability of survival all causes of death in Korean Association of Lung Cancer Registry patients,

^b) Expected survival rate: probability of expected survivors in a comparable cohort of cancer-free general population.

REFERENCES

1. Park S, Choi CM, Hwang SS, Choi YL, Kim HY, Kim YC, et al. Lung cancer in Korea. J Thorac Oncol. 2021;16:1988–93. Article PubMed
2. Hong S, Won YJ, Lee JJ, Jung KW, Kong HJ, Im JS, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021;53:301–15. Article PubMed PMC PDF
3. Bar J, Urban D, Amit U, Appel S, Onn A, Margalit O, et al. Long-term survival of patients with metastatic non-small-cell lung cancer over five decades. J Oncol. 2021;2021:7836264.Article PubMed PMC PDF
4. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. Article PubMed PDF
5. National Cancer Institute. Surveillance, Epidemiology, and End Results program. SEER*Stat Database. Bethesda, MD: National Cancer Institute; 2021.
6. Wong MC, Lao XQ, Ho KF, Goggins WB, Tse SL. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7:14300.Article PubMed PMC PDF
7. Kim YC, Won YJ. The development of the Korean Lung Cancer Registry (KALC-R). Tuberc Respir Dis. 2019;82:91–3. Article PDF
8. Dickman PW, Coviello E. Estimating and modeling relative survival. Stata J. 2015;15:186–215. Article PDF
9. Statistics Korea [Internet]. Daejeon: Statistics Korea; 2020. [cited 2022 May 30]. Available from: https://kostat.go.kr/portal/korea/index.action
10. Choi CM, Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, et al. Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. Cancer Res Treat. 2019;51:1400–10. Article PubMed PMC PDF
11. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–57. Article PubMed
12. Sachs E, Sartipy U, Jackson V. Sex and survival after surgery for lung cancer: a Swedish nationwide cohort. Chest. 2021;159:2029–39. Article PubMed
13. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618–26. Article PubMed
14. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5:620–30. Article PubMed
15. Zhou K, Shi H, Chen R, Cochuyt JJ, Hodge DO, Manochakian R, et al. Association of race, socioeconomic factors, and treatment characteristics with overall survival in patients with limited-stage small cell lung cancer. JAMA Netw Open. 2021;4:e2032276.Article PubMed PMC
16. Hong S, Cho BC, Choi HJ, Jung M, Lee SH, Park KS, et al. Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients. Oncology. 2010;79:293–300. Article PubMed PDF
17. Hiddinga BI, Raskin J, Janssens A, Pauwels P, Van Meerbeeck JP. Recent developments in the treatment of small cell lung cancer. Eur Respir Rev. 2021;30:210079.Article PubMed PMC
18. Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8:1–20. Article PubMed PMC
19. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301–11. Article PubMed PMC
20. Yun JK, Lee GD, Kim HR, Kim YH, Kim DK, Park SI, et al. Validation of the 8th edition of the TNM staging system in 3,950 patients with surgically resected non-small cell lung cancer. J Thorac Dis. 2019;11:2955–64. Article PubMed PMC
21. Akhtar-Danesh N, Finley C. Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: a population-based study. Lung Cancer. 2015;90:8–14. Article PubMed
22. Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943–53. PubMed PMC
23. Shin A, Oh CM, Kim BW, Woo H, Won YJ, Lee JS. Lung cancer epidemiology in Korea. Cancer Res Treat. 2017;49:616–26. Article PubMed PDF
24. Campos-Balea B, de Castro Carpeno J, Massuti B, Vicente-Baz D, Perez Parente D, Ruiz-Gracia P, et al. Prognostic factors for survival in patients with metastatic lung adenocarcinoma: an analysis of the SEER database. Thorac Cancer. 2020;11:3357–64. Article PubMed PMC PDF
25. Giroux Leprieur E, Lavole A, Ruppert AM, Gounant V, Wislez M, Cadranel J, et al. Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirology. 2012;17:134–42. Article PubMed
26. Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Janne PA, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 2016;11:556–65. Article PubMed
27. Huang CY, Chen BH, Chou WC, Yang CT, Chang JW. Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. J Thorac Dis. 2018;10:2070–8. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis
Junfang Zhang, Xuan Tang, Wenbo Zhang, Ying Xu, Heng Zhang, Yu Fan
International Journal of Obesity.2025; 49(1): 13. CrossRef
Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim
Cancer Research and Treatment.2024; 56(1): 104. CrossRef
The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round
Alberto Antonicelli, Piergiorgio Muriana, Giovanni Favaro, Giuseppe Mangiameli, Ezio Lanza, Manuel Profili, Fabrizio Bianchi, Emanuela Fina, Giuseppe Ferrante, Simone Ghislandi, Daniela Pistillo, Giovanna Finocchiaro, Gianluigi Condorelli, Rosalba Lembo,
Cancers.2024; 16(2): 417. CrossRef
Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
Hyeon Hwa Kim, Jae Cheol Lee, In-Jae Oh, Eun Young Kim, Seong Hoon Yoon, Shin Yup Lee, Min Ki Lee, Jeong Eun Lee, Chan Kwon Park, Kye Young Lee, Sung Yong Lee, Seung Joon Kim, Jun Hyeok Lim, Chang-min Choi
Cancers.2024; 16(3): 528. CrossRef
Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation
Theofanis Vavilis, Maria Louiza Petre, Giannis Vatsellas, Alexandra Ainatzoglou, Eleni Stamoula, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas, Ioannis N. Vamvakaris, Ioannis Gkiozos, Konstantinos N. Syrigos, Athanasios K. Anagnostopoulos
Cancers.2024; 16(6): 1236. CrossRef
Survival analysis and gender differences in hypertrophic cardiomyopathy proband patients referred for genetic testing
Rebeca Lorca, María Salgado, Rut Álvarez-Velasco, Julián R. Reguro, Vanesa Alonso, Juan Gómez, Eliecer Coto, Elías Cuesta-Llavona, Eva Lopez-Negrete, Isaac Pascual, Pablo Avanzas, Maite Tome
International Journal of Cardiology.2024; 408: 132117. CrossRef
18F-Fluorodeoxyglucose Positron Emission Tomography-Based Risk Score Model for Prediction of Five-Year Survival Outcome after Curative Resection of Non-Small-Cell Lung Cancer
Chae Hong Lim, Sang-Won Um, Hong Kwan Kim, Yong Soo Choi, Hong Ryul Pyo, Myung-Ju Ahn, Joon Young Choi
Cancers.2024; 16(14): 2525. CrossRef
Study Progress of Circulating miRNA for Predicting Metastasis in Non-Small Cell Lung Cancer
靖靖丛
Advances in Clinical Medicine.2024; 14(07): 65. CrossRef
Toll-like Receptors: Key Players in Squamous Cell Carcinoma Progression
Jolanta Smok-Kalwat, Paulina Mertowska, Sebastian Mertowski, Stanisław Góźdź, Ewelina Grywalska
Journal of Clinical Medicine.2024; 13(15): 4531. CrossRef
Timing of Palliative Care Consultation Impacts End of Life Care Outcomes in Metastatic Non-Small Cell Lung Cancer
Cameron J. Oswalt, Morgan M. Nakatani, Jesse Troy, Steven Wolf, Susan C. Locke, Thomas W. LeBlanc
Journal of Pain and Symptom Management.2024; 68(4): e325. CrossRef
Enhanced Lung Cancer Detection Using a Combined Ratio of Antigen–Autoantibody Immune Complexes against CYFRA 21-1 and p53
Heyjin Kim, Jin Kyung Lee, Hye-Ryoun Kim, Young Jun Hong
Cancers.2024; 16(15): 2661. CrossRef
Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosome DNA Methylation Profile
Chinbayar Batochir, In Ae Kim, Eun Ji Jo, Eun-Bi Kim, Hee Joung Kim, Jae Young Hur, Do Won Kim, Hee Kyung Park, Kye Young Lee
Cancers.2024; 16(15): 2765. CrossRef
The clinical significance of endoplasmic reticulum stress related genes in non-small cell lung cancer and analysis of single nucleotide polymorphism for CAV1
Shuang Li, Junting Chen, Baosen Zhou
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef
A Highly Sensitive Toluene Gas Sensor Based on Pd/PdO Decorated SnO2 Prepared by Electrospinning
Chengyi Gong, Meng Chen, Fei Song, Peisi Yin, Xin Zhao, Xiaoyu You, Huaian Fu, Shanshan Yu, Xingyu Liu, Kai Zhang, Yongqi Yang, Zhipeng Tang, Xiangmin Du, Jiacong Xu, Qiang Jing, Bo Liu
ACS Applied Electronic Materials.2024;[Epub] CrossRef
miR-137: a potential therapeutic target for lung cancer
Shuanshuan Liu, Yanyun Ruan, Xu Chen, Bao He, Qi Chen
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef
Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer
Tianxing Hu, Jiali Huang, Rui Chen, Hui Zhang, Mai Liu, Renbing Wang, Wenyi Zhou, Dechun Huang, Mingkang Cao, Depeng Li, Zhiyu Li, Hongxi Wu, Jinlei Bian
European Journal of Medicinal Chemistry.2024; 280: 116952. CrossRef
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Suet Kee Loo, Gabriel Sica, Xian Wang, Tingting Li, Luping Chen, Autumn Gaither-Davis, Yufei Huang, Timothy F. Burns, Laura P. Stabile, Shou-Jiang Gao
Cell & Bioscience.2024;[Epub] CrossRef
Methylation modification is a poor prognostic factor in non-small cell lung Cancer and regulates the tumor microenvironment: mRNA molecular structure and function
Kai Yang, YuPing Yang, Lin Yu, Fan Yang, YuXin Xiang, Jun Zeng, Na Huang
International Journal of Biological Macromolecules.2024; 282: 137214. CrossRef
Impact of Postoperative Prolonged Air Leakage on Long-Term Pulmonary Function after Lobectomy for Lung Cancer
June Yeop Lee, Joonseok Lee, Varissara Javakijkarnjanakul, Beatrice Chia-Sui Shih, Woohyun Jung, Jae Hyun Jeon, Kwhanmien Kim, Sanghoon Jheon, Sukki Cho
Journal of Chest Surgery.2024; 57(6): 511. CrossRef
M1 macrophage-related prognostic model by combining bulk and single-cell transcriptomic data in NSCLC
Liu Zhe, Liu Fang, Petinrin Olutomilayo Olayemi, Toseef Muhammad, Chen Nanjun, Zhu Zhongxu, Wong Ka-Chun
Exploration of Medicine.2024;[Epub] CrossRef
Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors
Fabrice N. Njotu, Jessica Pougoue Ketchemen, Hanan Babeker, Nikita Henning, Anjong F. Tikum, Emmanuel Nwangele, Alissar Monzer, Nava Hassani, Brian D. Gray, Koon Y. Pak, Emina E. Torlakovic, Maruti Uppalapati, Humphrey Fonge
European Journal of Nuclear Medicine and Molecular Imaging.2024;[Epub] CrossRef
Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring
Michele Tomanelli, Federica Guffanti, Giulia Vargiu, Edoardo Micotti, Mara Rigamonti, Francesca Tumiatti, Elisa Caiola, Mirko Marabese, Massimo Broggini
Frontiers in Oncology.2024;[Epub] CrossRef
Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection
Silvia D’Ambrosi, Stavros Giannoukakos, Mafalda Antunes-Ferreira, Carlos Pedraz-Valdunciel, Jillian W. P. Bracht, Nicolas Potie, Ana Gimenez-Capitan, Michael Hackenberg, Alberto Fernandez Hilario, Miguel A. Molina-Vila, Rafael Rosell, Thomas Würdinger, Da
International Journal of Molecular Sciences.2023; 24(5): 4881. CrossRef
Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer: a single-center analysis of 10 years
Jee Seon Kim, Eun Ji Kim, Jong Geol Jang, Kyung Soo Hong, June Hong Ahn
Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7275. CrossRef
Prior treated tuberculosis and mortality risk in lung cancer
Kuang-Ming Liao, Chung-Shu Lee, Yu-Cih Wu, Chin-Chung Shu, Chung-Han Ho
Frontiers in Medicine.2023;[Epub] CrossRef
All-round counterattack to conquer lung cancer
Seung Hun Jang
Journal of the Korean Medical Association.2023; 66(3): 154. CrossRef
Metabolic profiles of lung adenocarcinoma via peripheral blood and diagnostic model construction
Kyung Soo Kim, Seok Whan Moon, Mi Hyung Moon, Kwan Yong Hyun, Seung Joon Kim, Young Koon Kim, Kwang Youl Kim, Dong Wook Jekarl, Eun-Jee Oh, Yonggoo Kim
Scientific Reports.2023;[Epub] CrossRef
STEMI in women. Life expectancy recovery after primary percutaneous coronary intervention
Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
Revista Española de Cardiología (English Edition).2023; 76(12): 1003. CrossRef
A Retrospective Analysis Comparing VATS Cost Discrepancies and Outcomes in Primary Lung Cancer vs. Second Primary Lung Cancer Patients
Bogdan Cosmin Tanase, Alin Ionut Burlacu, Claudiu Eduard Nistor, Teodor Horvat, Cristian Oancea, Monica Marc, Emanuela Tudorache, Tudor Mateescu, Diana Manolescu
Healthcare.2023; 11(12): 1745. CrossRef
IAMCEST en mujeres. Recuperación de la expectativa de vida tras la intervención coronaria percutánea
Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
Revista Española de Cardiología.2023; 76(12): 1003. CrossRef
Synthetic Tabular Data Based on Generative Adversarial Networks in Health Care: Generation and Validation Using the Divide-and-Conquer Strategy
Ha Ye Jin Kang, Erdenebileg Batbaatar, Dong-Woo Choi, Kui Son Choi, Minsam Ko, Kwang Sun Ryu
JMIR Medical Informatics.2023; 11: e47859. CrossRef
Exosomes in lung cancer metastasis, diagnosis, and immunologically relevant advances
Jianhua Zhao, Xiwen Li, Lele Liu, Zhen Zhu, Chunyan He
Frontiers in Immunology.2023;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

Cancer Res Treat. 2023;55(1):103-111. Published online June 20, 2022

DOI: https://doi.org/10.4143/crt.2022.264

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

Fig. 1 Overall survival in patients with non–small cell lung cancer (NSCLC), according to clinical stage.

Fig. 2 Overall survival in patients with small cell lung cancer (SCLC), according to clinical stage. ED, extensive disease; LD, limited disease.

Fig. 1

Fig. 2

Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

Table 1

Baseline characteristics of patients with NSCLC in 2015

	Total	Non-survivor	Survivor	p-value
No. of patients	2,098	1,446 (68.9)	652 (31.1)
Male sex	1,464 (69.8)	1,091 (75.4)	373 (57.2)	< 0.001
Age (yr)	69.0 (60.0–75.0)	70.0 (62.0–76.0)	65.0 (57.0–72.0)	< 0.001
Ever-smoker	1,328 (63.3)	976 (67.5)	352 (54.0)	< 0.001
BMI (kg/m ² )	23.0 (22.2–24.1)	22.9 (21.6–24.2)	23.4 (23.1–23.8)	0.402
Symptoms	2,062	1,419	643
Asymptomatic	322 (15.6)	127 (8.9)	195 (30.3)	< 0.001
Cough	697 (33.8)	548 (38.6)	149 (23.2)	< 0.001
Sputum	406 (19.7)	310 (21.8)	96 (15.0)	< 0.001
Dyspnea	374 (18.1)	320 (22.6)	54 (8.4)	< 0.001
Hoarseness	47 (2.3)	42 (3.0)	5 (0.8)	0.002
Hemoptysis	128 (6.2)	100 (7.0)	28 (4.4)	0.020
Weight loss	116 (5.6)	94 (6.6)	22 (3.4)	0.004
Pain	381 (18.5)	320 (22.6)	61 (9.5)	< 0.001
Histopathology	2,098	1,446	652
Adenocarcinoma	1,308 (62.3)	810 (56.0)	498 (76.4)	< 0.001
Squamous cell carcinoma	662 (31.6)	522 (36.1)	140 (21.5)	< 0.001
Others	247 (11.8)	208 (14.4)	39 (6.0)	< 0.001
Performance status	1,550	1,029	521	< 0.001
0–1	1,371 (88.5)	862 (83.8)	511 (98.1)
2–4	177 (11.4)	167 (16.2)	10 (1.9)
Clinical stage of NSCLC	1,818	1,243	575	< 0.001
I	390 (21.5)	91 (7.3)	299 (52.0)
II	261 (14.4)	122 (9.8)	139 (24.2)
III	653 (35.9)	559 (45.0)	94 (16.3)
IV	514 (28.3)	471 (37.9)	43 (7.5)

Values are presented as the number (%) or median (interquartile range). BMI, body mass index; NSCLC, non–small cell lung cancer.

Table 2

Baseline characteristics of patients with SCLC in 2015

	Total	Non-survivor	Survivor	p-value
No. of patients	345	321	24
Male sex	292 (84.6)	272 (84.7)	20 (83.3)	0.854
Age (yr)	71.0 (63.0–76.0)	72.0 (63.0–77.0)	67.5 (60.0–71.0)	0.023
Ever-smoker	289 (83.8)	268 (83.5)	21 (87.5)	0.381
BMI (kg/m ² )	25.6 (22.4–30.0)	25.9 (22.2–30.9)	22.5 (20.0–24.3)	0.166
Symptoms	342	318	24
Asymptomatic	20 (5.8)	18 (5.7)	2 (8.3)	0.581
Cough	157 (45.9)	146 (45.9)	11 (45.8)	0.973
Sputum	99 (28.9)	95 (29.9)	4 (16.7)	0.177
Dyspnea	108 (31.6)	103 (32.4)	5 (20.8)	0.251
Hoarseness	11 (3.2)	10 (3.1)	1 (4.2)	0.777
Hemoptysis	19 (5.6)	17 (5.3)	2 (8.3)	0.529
Weight loss	31 (9.1)	31 (9.7)	0	0.111
Pain	62 (18.1)	61 (19.2)	1 (4.2)	0.068
Performance status	272	256	16	0.681
0–1	228 (83.8)	214 (83.6)	14 (87.5)
2–4	44 (16.2)	42 (16.4)	2 (12.5)
Clinical stage of SCLC	345	321	24	0.004
LD	122 (35.4)	106 (33.0)	16 (66.7)
ED	213 (61.7)	205 (63.9)	8 (33.3)
Unknown	10 (2.9)	10 (3.1)	0

Values are presented as the number (%) or median (interquartile range). BMI, body mass index; ED, extensive disease; LD, limited disease; SCLC, small cell lung cancer.

Table 3

Risk factors for mortality in patients with NSCLC assessed by Cox proportional hazards model

	Univariate analysis			Multivariate analysis

	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age	1.032	1.027–1.038	< 0.001	1.019	1.012–1.025	< 0.001

Male sex	1.714	1.520–1.933	< 0.001	1.222	0.985–1.516	0.069

Ever-smoker	1.490	1.332–1.667	< 0.001	1.112	0.899–1.375	0.327

BMI	0.998	0.995–1.002	0.444

Performance status

0–1 (ref)	1.000			1.000

2–4	3.172	2.681–3.753	< 0.001	1.995	1.655–2.405	< 0.001

Clinical stage

I (ref)	1.000			1.000

II	2.434	1.855–3.194	< 0.001	1.530	1.084–2.159	0.016

III	7.801	6.241–9.750	< 0.001	3.263	2.407–4.423	< 0.001

IV	8.574	6.836–10.754	< 0.001	3.829	2.814–5.211	< 0.001

Histology

Adenocarcinoma (ref)	1.000			1.000

Squamous cell carcinoma	1.648	1.476–1.841	< 0.001	1.203	1.033–1.402	0.018

Treatment

Surgery (ref)	1.000			1.000

Non-surgical treatment	6.889	5.708–8.314	< 0.001	3.814	2.968–4.902	< 0.001

Best supportive care	10.232	8.399–12.466	< 0.001	5.189	3.945–6.826	< 0.001

BMI, body mass index; CI, confidence interval; NSCLC, non smallcell lung cancer.

Table 4

Risk factors for mortality in patients with SCLC assessed by Cox proportional hazards model

	Univariate analysis			Multivariate analysis

	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age	1.042	1.028–1.056	< 0.001	1.041	1.026–1.057	< 0.001

Male sex	1.079	0.796–1.463	0.622

Ever-smoker	0.685	0.504–0.929	0.015	0.736	0.509–1.062	0.101

BMI	1.000	0.997–1.004	0.787

Performance status

0–1 (ref)	1.000			1.000

2–4	1.943	1.391–2.714	< 0.001	1.838	1.305–2.587	< 0.001

Clinical stage

LD (ref)	1.000			1.000

ED	1.961	1.542–2.493	< 0.001	2.144	1.636–2.810	< 0.001

Treatment

Anti-cancer treatment (ref)	1.000

Best supportive care	1.160	0.924–1.455	0.200

BMI, body mass index; CI, confidence interval; ED, extensive disease; LD, limited disease; SCLC, small cell lung cancer.

Table 5

Five-year relative survival rates of patients with NSCLC according to stage at lung cancer diagnosis

Stage	Time (yr)	No. at risk	No. of deaths	Observed survival rate^a)	Expected survival rate^b)	Relative survival (95% CI)
1	0.0–1.0	390	19	0.95	0.99	0.96 (0.93–0.98)
	1.0–2.0	371	22	0.89	0.98	0.91 (0.88–0.94)
	2.0–3.0	349	22	0.84	0.97	0.87 (0.82–0.90)
	3.0–4.0	327	16	0.80	0.96	0.83 (0.79–0.87)
	4.0–5.0	311	9	0.78	0.94	0.82 (0.77–0.86)
2	0.0–1.0	261	54	0.79	0.98	0.80 (0.75–0.85)
	1.0–2.0	207	26	0.69	0.97	0.72 (0.65–0.77)
	2.0–3.0	181	15	0.64	0.95	0.67 (0.60–0.73)
	3.0–4.0	166	16	0.57	0.94	0.61 (0.55–0.67)
	4.0–5.0	150	7	0.55	0.92	0.59 (0.53–0.66)
3	0.0–1.0	653	349	0.47	0.98	0.47 (0.43–0.51)
	1.0–2.0	304	105	0.30	0.97	0.31 (0.28–0.35)
	2.0–3.0	199	52	0.23	0.96	0.24 (0.20–0.27)
	3.0–4.0	147	27	0.18	0.94	0.20 (0.16–0.23)
	4.0–5.0	120	21	0.15	0.92	0.16 (0.14–0.19)
4	0.0–1.0	514	262	0.49	0.98	0.50 (0.45–0.54)
	1.0–2.0	252	112	0.27	0.97	0.28 (0.24–0.32)
	2.0–3.0	140	42	0.19	0.95	0.20 (0.17–0.24)
	3.0–4.0	98	30	0.13	0.94	0.14 (0.11–0.17)
	4.0–5.0	68	19	0.10	0.92	0.10 (0.08–0.13)

CI, confidence interval; NSCLC, non small cell lung cancer.

^a)Observed survival rate: probability of survival all causes of death in Korean Association of Lung Cancer Registry patients,

^b)Expected survival rate: probability of expected survivors in a comparable cohort of cancer-free general population.

Table 6

Five-year relative survival rates of patients with SCLC according to stage at lung cancer diagnosis

Stage	Time (yr)	No. at risk	No. of deaths	Observed survival rate^a)	Expected survival rate^b)	Relative survival (95% CI)
LD	0.0–1.0	122	56	0.54	0.98	0.55 (0.49–0.64)
	1.0–2.0	66	27	0.32	0.97	0.33 (0.25–0.42)
	2.0–3.0	39	14	0.20	0.96	0.21 (0.14–0.29)
	3.0–4.0	25	5	0.16	0.95	0.17 (0.11–0.25)
	4.0–5.0	20	2	0.15	0.94	0.16 (0.10–0.23)
ED	0.0–1.0	213	156	0.27	0.98	0.27 (0.21–0.33)
	1.0–2.0	57	41	0.08	0.97	0.08 (0.05–0.12)
	2.0–3.0	16	6	0.05	0.96	0.05 (0.03–0.08)
	3.0–4.0	10	1	0.04	0.95	0.04 (0.02–0.08)
	4.0–5.0	9	1	0.04	0.95	0.04 (0.02–0.07)

CI, confidence interval; ED, extensive disease; LD, limited disease; SCLC, small cell lung cancer.

^a)Observed survival rate: probability of survival all causes of death in Korean Association of Lung Cancer Registry patients,

^b)Expected survival rate: probability of expected survivors in a comparable cohort of cancer-free general population.

Table 1 Baseline characteristics of patients with NSCLC in 2015

Values are presented as the number (%) or median (interquartile range). BMI, body mass index; NSCLC, non–small cell lung cancer.

Table 2 Baseline characteristics of patients with SCLC in 2015

Values are presented as the number (%) or median (interquartile range). BMI, body mass index; ED, extensive disease; LD, limited disease; SCLC, small cell lung cancer.

Table 3 Risk factors for mortality in patients with NSCLC assessed by Cox proportional hazards model

BMI, body mass index; CI, confidence interval; NSCLC, non smallcell lung cancer.

Table 4 Risk factors for mortality in patients with SCLC assessed by Cox proportional hazards model

BMI, body mass index; CI, confidence interval; ED, extensive disease; LD, limited disease; SCLC, small cell lung cancer.

Table 5 Five-year relative survival rates of patients with NSCLC according to stage at lung cancer diagnosis

CI, confidence interval; NSCLC, non small cell lung cancer.

Observed survival rate: probability of survival all causes of death in Korean Association of Lung Cancer Registry patients,

Expected survival rate: probability of expected survivors in a comparable cohort of cancer-free general population.

Table 6 Five-year relative survival rates of patients with SCLC according to stage at lung cancer diagnosis

CI, confidence interval; ED, extensive disease; LD, limited disease; SCLC, small cell lung cancer.

Observed survival rate: probability of survival all causes of death in Korean Association of Lung Cancer Registry patients,

Expected survival rate: probability of expected survivors in a comparable cohort of cancer-free general population.